Brought to you by 
Series A brings $7.25mm to start-up Acetylon; adds $2mm
14 Jan 2021
Executive Summary
Acetylon Pharmaceuticals raised $7.25mm through the sale of Series A preferred shares to the Kraft Group and several individuals including the company's co-founder, who was recently appointed chairman.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A brings $7.25mm to start-up Acetylon; adds $2mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice